Mostrar o rexistro simple do ítem

dc.contributor.authorValladares-Ayerbes, Manuel
dc.contributor.authorIglesias-Díaz, Pilar
dc.contributor.authorDíaz-Prado, Silvia
dc.contributor.authorAyude, Daniel
dc.contributor.authorMedina Villaamil, Vanessa
dc.contributor.authorHaz, Mar
dc.contributor.authorReboredo, Margarita
dc.contributor.authorAntolín, Silvia
dc.contributor.authorCalvo, Lourdes
dc.contributor.authorAntón-Aparicio, Luis M.
dc.date.accessioned2018-05-09T09:49:52Z
dc.date.available2018-05-09T09:49:52Z
dc.date.issued2009-02-17
dc.identifier.citationValladares-Ayerbes M, Iglesias-Díaz P, Díaz-Prado S, Ayude D, Medina V, Haz M, et al. Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study. J Cancer Res Clin Oncol. 2009:135(9):1185-1195.es_ES
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.urihttp://hdl.handle.net/2183/20696
dc.description.abstract[Abstract] Background. Detection of isolated tumour cells (ITC) in the blood or minimal deposits in distant organs such as bone marrow (BM) could be important to identify breast cancer patients at high risk of relapse or disease progression. PCR amplification of tissue or tumour selective mRNA is the most powerful analytical tool for detection of this micrometastasis. We have evaluated for the first time, the diagnostic accuracy of small breast epithelial mucin (SBEM) as a potential marker for BM micrometastasis in breast cancer. Methods. A nested RT-PCR assay for detection of SBEM mRNA was compared with immunocytochemistry (ICC) with anticytokeratin AE1/AE3 antibody in paired samples obtained from the BM of breast cancer patients. Associations of SBEM mRNA detection in BM and clinical and pathological parameters were evaluated. SBEM mRNA status and time to breast cancer progression were analysed using Kaplan–Meyer curves. Results. Fifty stages I–IV breast cancer female patients were prospectively included in our study. SBEM specific transcript was found in BM in 26% of the patients. Detection rate was similar to the percentage of patients with ITCs detected using ICC (24%). SBEM mRNA in BM aspirates were significantly associated with presence of clinically active disease, including locally advanced and metastatic patients (47%, P = 0.021) and tumours with positive hormonal receptors (36.7%, P = 0.035). In addition association with Her2/neu over-expression (44.4%, P = 0.051) and low proliferating tumours (36%, P = 0.067) were close to significant levels. When we analysed time to breast cancer progression adjusting for grade or hormone receptor status, presence of SBEM mRNA in BM defines distinct prognostic groups. Conclusions. SBEM might represent a suitable marker for molecular detection of ITCs in BM in breast cancer patients. Analysis of prognostic value for SBEM mRNA-based assay should take into account the heterogeneity and different molecular subtypes of breast cancer.es_ES
dc.description.sponsorshipThis study was supported by grant 2000-5435256011 from Universidade da Coruña. S. Díaz-Prado is supported by an Isidro Parga Pondal research contract by Xunta de Galicia.es_ES
dc.language.isoenges_ES
dc.publisherSpringer-Verlages_ES
dc.relation.urihttps://doi.org/10.1007/s00432-009-0559-7es_ES
dc.rightsThe final publication is avaliable at Springer Linkes_ES
dc.subjectIsolated tumour cellses_ES
dc.subjectSmall breast epithelial mucines_ES
dc.subjectBreast tumour cellses_ES
dc.subjectMinimal diseasees_ES
dc.subjectRNA-based methodses_ES
dc.titleDiagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleJournal of Cancer Research and Clinical Oncologyes_ES
UDC.volume135es_ES
UDC.issue9es_ES
UDC.startPage1185es_ES
UDC.endPage1195es_ES


Ficheiros no ítem

Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem